REDWOOD CITY, Calif., Nov. 23 /PRNewswire/ -- Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced the appointment of Howie Rosen to the company's Board of Directors. Mr. Rosen has 25 years of experience in the pharmaceutical and biotechnology industries, including key roles at Gilead Sciences and ALZA Corporation. His appointment increases the number of directors on Pearl's Board to six.
"Howie brings a wealth of product development, commercialization and general management experience to Pearl, having held senior positions at some of the leading companies in the industry," said Perry Karsen, Chief Executive Officer of Pearl Therapeutics. "His proven track record in the drug delivery market will be invaluable to Pearl as we advance our proprietary products toward late-stage development for the treatment of chronic obstructive pulmonary disease."
"I look forward to working with Pearl's Board and management team to help develop and commercialize their very promising products for the treatment of serious, highly prevalent respiratory diseases," said Mr. Rosen. "Because of Pearl's distinctive technology platform, their products have the potential to offer patients and clinicians many compelling advantages over currently available therapies."
Mr. Rosen is currently a consultant to several companies in the industry and a lecturer in the Department of Chemical Engineering at Stanford University. He previously served as Vice President, Commercial Strategy, at Gilead Sciences, Inc., where he was responsible for strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to Gilead, Mr. Rosen spent more than 10 years in various roles at ALZA Corporation, an operating company within the Johnson & Johnson Family of Companies
|Copyright©2009 PR Newswire.|
All rights reserved